

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re patent application:  
FARHAD PARHAMI

U.S. Application No.: 10/524,945

Confirmation No.: 3129

Filed: February 16, 2005

Title: AGENTS AND METHODS FOR  
ENHANCING BONE  
FORMATION

Art Unit: 1633

Examiner: Maria Gomez Leavitt

Atty. Docket No.: 58086-241892

Customer No.

**26694**

PATENT TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Copies of documents C1 – C8 are enclosed.

This Information Disclosure Statement is filed after the mailing date of a first Office Action, but before the mailing date of a final Action or a Notice of Allowance as far as is known to the undersigned (37 CFR 1.97(c)). The Director is hereby authorized to charge the fee of \$180 due under 37 CFR 1.17(p) and 1.97(c)(2) to Deposit Account No. 22-0261, under Order No. 58086-241892.


In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 58086-241892.

Respectfully submitted,



Dated: April 1, 2010

Nancy Axelrod, Ph.D.  
Registration No. 44,014  
VENABLE LLP  
P.O. Box 34385  
Washington, DC 20043-9998  
202-344-4000  
202-344-8300 (fax)

DC2/1098507